Anew Labs
新生实验室
Anew Labs is an AI-driven drug discovery company spun out of ByteDance.
Position in SVTR
Snapshot 2026-11-05- Startup SignalsTop 10%↓8
- Life SciencesTop 10%↓1
- AI for ScienceTop 25%–
- Drug Discovery#8of 68–
About
Anew Labs is an AI-driven drug discovery company spun out of ByteDance. Its team was formed inside ByteDance in 2021 by Liu Kai and was spun off as an independent company in June 2026, headquartered in Yangpu, Shanghai, with offices in the US and Singapore. It builds AI drug-discovery platforms (AnewFold, AnewSampling, AnewOmni, AnewDesign, AnewMind) spanning protein structure prediction, all-atom molecular generation, antibody design and scientific reasoning, with a pipeline of preclinical candidates including a small-molecule inhibitor targeting IL-17 family dimers.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Company· 12
Investor· 9
Founders / team· 1
Funding history
- 2026-09-16New funding round$290M
Investors · HongShan, 5Y Capital, Primavera Venture Partners, IDG Capital, GL Ventures, Boyu Capital, SBP Group, Gaorong Ventures, Shanghai Future Industries FundSource · reuters.com ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Anew Labs
AI-driven drug discovery and new drug development platform
Undisclosed · $290M · 2026-09
$290M
United States
BusinessLatest roundTotal raisedDate- Aureka Biotechnologies
AuraIDE™, a platform for generative antibody drug discovery and functional antibody design
Series B · $200M · 2026-08
$200M - LifeMine Therapeutics
A clinical-stage precision drug discovery company based on fungal genome mining, developing novel therapies in transplantation and immunology.
Series D+ · $558M · 2026-08
$558M - Iambic Therapeutics
Uses AI to predict protein-ligand structures and generate molecular designs to discover new drugs
IPO · $462M · 2026-09
$462M
China
BusinessLatest roundTotal raisedDate- Insilico Medicine
AI drug discovery company that uses generative models for target discovery and molecular design…
Series D+ · $210M · 2025-03
$210M - Deep Pharma
AI-driven drug discovery and clinical development platform
Series D+ · $200M · 2026-03
$200M - Syneron Bio
AI-driven synthetic peptide drug developer focused on a pipeline of next-generation synthetic peptide and protein drugs
Series B · $280M · 2026-04
$280M
Europe
BusinessLatest roundTotal raisedDate- Turbine
Uses AI to simulate biological experiments, accelerating drug discovery and translational research
Series B · $25M · 2026-03
$25M - Isomorphic Labs
AI-driven drug design platform (IsoDDE engine): uses AlphaFold-based technology to predict protein structures and design new drug molecules; builds it…
Series B · $2.7B · 2026-05
$2.7B - Helical
Turns biology AI foundation models into reproducible drug discovery workflows for pharma teams
Seed · $20M · 2026-04
$20M
Other / unspecified
BusinessLatest roundTotal raisedDate- 深度细胞
Combines AI with multiscale molecular physics to build a "virtual cell world model" for disease mechanism discovery and drug design
Seed · $14M · 2026-08
$14M - Miles Wang 新公司
Develops AI models for drug discovery
— - Astellas Pharma
Research, manufacturing and sale of prescription drugs in oncology, ophthalmology, urology, immunology and women's health.
—
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Related coverage
Investors that may fit
Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.